Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
- Address
- Am Bahnhofsplatz 5, 31134 Hildesheim, Germany
Breast Cancer Research
At Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz in Hildesheim, most clinical trial activity focuses on neoplasms, especially a wide range of breast cancer types. The studies explore new ways to improve outcomes for patients with HER2-positive, HR-positive, and triple-negative disease, including both early and advanced stages.
- Testing new treatment strategies for HER2+ early breast cancer and high-risk HER2-positive breast cancer
- Evaluating approaches for ER+/HER2- and HR+/HER2- early breast cancer to improve long-term disease control
- Studying treatment effectiveness in triple-negative early breast cancer, including lower-risk and stage II-III disease
- Assessing therapy options for HR+/HER2- advanced breast cancer after prior hormone-based treatment
These trials are designed to test whether newer targeted and personalized treatments can improve survival, reduce recurrence, and support better care compared with standard treatment options.
Gynecologic Oncology
The site also contributes to research in female urogenital diseases, with a strong focus on epithelial ovarian cancer. This work looks at maintaining disease control after surgery and chemotherapy, while also considering how treatment affects patients’ daily well-being.
- Exploring maintenance treatment strategies for epithelial ovarian cancer
- Evaluating whether ongoing therapy can delay progression after standard treatment
- Supporting research aimed at improving quality of life during cancer care
Overall, the research in this area is centered on finding better ways to extend progression-free survival and refine follow-up treatment for women with ovarian cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 2 | Unknown | 2024-10-10 | 2024-10-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.